Replication-competent herpes simplex vectors: design and applications.

about

Gene therapy in keratoconus Replicating and non-replicating viral vectors for vaccine development

P2860

Q35098491-E69F8486-48EF-4712-8EE0-E7C8C0727A92 Q36464587-2282E15D-8FA2-45C4-8E36-9F1AC2E5649D

P2860

Replication-competent herpes simplex vectors: design and applications.

Item

http://www.wikidata.org/entity/Q36288909

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Replication-competent herpes simplex vectors: design and applications.

@ast

Replication-competent herpes simplex vectors: design and applications.

@en

type

Item

label

Replication-competent herpes simplex vectors: design and applications.

@ast

Replication-competent herpes simplex vectors: design and applications.

@en

prefLabel

Replication-competent herpes simplex vectors: design and applications.

@ast

Replication-competent herpes simplex vectors: design and applications.

@en

P1476

Replication-competent herpes simplex vectors: design and applications.

@en

P2093

Argnani R

http://www.w3.org/2001/XMLSchema#string

Lufino M

http://www.w3.org/2001/XMLSchema#string

Manservigi M

http://www.w3.org/2001/XMLSchema#string

Manservigi R

http://www.w3.org/2001/XMLSchema#string

P2860

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

A herpes simplex virus type 1 gamma34.5 second-site suppressor mutant that exhibits enhanced growth in cultured glioblastoma cells is severely attenuated in animals

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma.

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Recent progress in herpes simplex virus immunobiology and vaccine research

Viral oncolysis.

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.

Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors.

Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas.

P2888

sj.gt.3302622

P304

S170-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.GT.3302622

http://www.w3.org/2001/XMLSchema#string

P478

12 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P577

2005-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7535483

http://www.w3.org/2001/XMLSchema#string

P698

16231051

http://www.w3.org/2001/XMLSchema#string

Replication-competent herpes simplex vectors: design and applications.

about

P2860

P2860

Replication-competent herpes simplex vectors: design and applications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P577

P5875

P698